Literature DB >> 34645275

Association of Cannabis Use-Related Predictor Variables and Self-Reported Psychotic Disorders: U.S. Adults, 2001-2002 and 2012-2013.

Ofir Livne1, Dvora Shmulewitz1, Aaron L Sarvet1, Melanie M Wall1, Deborah S Hasin1.   

Abstract

OBJECTIVE: The authors sought to determine the association of cannabis indicators with self-reported psychotic disorders in the U.S. general population.
METHODS: Participants were from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC; 2001-2002; N=43,093) and NESARC-III (2012-2013; N=36,309). Logistic regression was used to estimate standardized prevalences of past-year self-reported psychotic disorders within each survey and to evaluate the association of past-year self-reported psychotic disorders with indicators of nonmedical cannabis use (any use; frequent use [at least three times/week], daily/near-daily use, and DSM-IV cannabis use disorder) compared with those with no past-year nonmedical cannabis use. Whether the strength of associations differed between surveys was indicated by difference-in-difference tests (between-survey contrasts) and ratios of odds ratios between surveys.
RESULTS: Self-reported psychotic disorders were significantly more prevalent among participants with any nonmedical cannabis use than those without (2001-2002: 1.65% compared with 0.27%; 2012-2013: 1.89% compared with 0.68%). In 2001-2002, self-reported psychotic disorders were unrelated to either frequent use or daily/near-daily use. However, in 2012 - 2013, compared with nonusers, self-reported psychotic disorders were more common among participants with frequent use and those with daily/near-daily nonmedical cannabis use (2012-2013: 2.79% and 2.52%, respectively, compared with 0.68% among nonusers). Self-reported psychotic disorders were significantly more prevalent among participants with cannabis use disorder than nonusers in both surveys (2001-2002: 2.55% compared with 0.27%; 2012 - 2013: 3.38% compared with 0.68%). The strength of these associations did not change over time.
CONCLUSIONS: Data from the U.S. general population, especially more recent data, suggest associations between self-reported psychotic disorder and frequent nonmedical cannabis use and cannabis use disorder. Clinicians and policy makers should consider these relationships when monitoring patients and formulating programs.

Entities:  

Keywords:  Cannabis; Psychotic Disorders; Substance-Related and Addictive Disorders

Mesh:

Year:  2021        PMID: 34645275      PMCID: PMC8945254          DOI: 10.1176/appi.ajp.2021.21010073

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   19.242


  63 in total

1.  Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study.

Authors:  Stanley Zammit; Peter Allebeck; Sven Andreasson; Ingvar Lundberg; Glyn Lewis
Journal:  BMJ       Date:  2002-11-23

2.  Recommendations for presenting analyses of effect modification and interaction.

Authors:  Mirjam J Knol; Tyler J VanderWeele
Journal:  Int J Epidemiol       Date:  2012-01-09       Impact factor: 7.196

3.  The validity of using patient self-report to assess psychotic symptoms in schizophrenia.

Authors:  Noosha Niv; Amy N Cohen; Jim Mintz; Joseph Ventura; Alexander S Young
Journal:  Schizophr Res       Date:  2007-01-03       Impact factor: 4.939

4.  New trends in cannabis potency in USA and Europe during the last decade (2008-2017).

Authors:  Suman Chandra; Mohamed M Radwan; Chandrani G Majumdar; James C Church; Tom P Freeman; Mahmoud A ElSohly
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-22       Impact factor: 5.270

5.  The widening gender gap in marijuana use prevalence in the U.S. during a period of economic change, 2002-2014.

Authors:  Hannah Carliner; Pia M Mauro; Qiana L Brown; Dvora Shmulewitz; Reanne Rahim-Juwel; Aaron L Sarvet; Melanie M Wall; Silvia S Martins; Geoffrey Carliner; Deborah S Hasin
Journal:  Drug Alcohol Depend       Date:  2016-11-11       Impact factor: 4.492

Review 6.  Cannabis Use and the Risk for Psychosis and Affective Disorders.

Authors:  Lucia Sideli; Harriet Quigley; Caterina La Cascia; Robin M Murray
Journal:  J Dual Diagn       Date:  2019-10-24

Review 7.  Size of burden of schizophrenia and psychotic disorders.

Authors:  Wulf Rössler; Hans Joachim Salize; Jim van Os; Anita Riecher-Rössler
Journal:  Eur Neuropsychopharmacol       Date:  2005-08       Impact factor: 4.600

8.  Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study.

Authors:  Marta Di Forti; Arianna Marconi; Elena Carra; Sara Fraietta; Antonella Trotta; Matteo Bonomo; Francesca Bianconi; Poonam Gardner-Sood; Jennifer O'Connor; Manuela Russo; Simona A Stilo; Tiago Reis Marques; Valeria Mondelli; Paola Dazzan; Carmine Pariante; Anthony S David; Fiona Gaughran; Zerrin Atakan; Conrad Iyegbe; John Powell; Craig Morgan; Michael Lynskey; Robin M Murray
Journal:  Lancet Psychiatry       Date:  2015-02-25       Impact factor: 27.083

9.  Prevalence of cannabis use disorder diagnoses among veterans in 2002, 2008, and 2009.

Authors:  Marcel O Bonn-Miller; Alex H S Harris; Jodie A Trafton
Journal:  Psychol Serv       Date:  2012-05-07

10.  Predictors and moderators of burden of care and emotional distress in first-episode psychosis caregivers: results from the GET UP pragmatic cluster randomised controlled trial.

Authors:  J Onwumere; C Bonetto; A Lasalvia; E Miglietta; A Veronese; F Bellini; M Imbesi; P Bebbington; E Kuipers; M Ruggeri
Journal:  Epidemiol Psychiatr Sci       Date:  2019-04-10       Impact factor: 6.892

View more
  1 in total

Review 1.  A Cannabinoid Hypothesis of Schizophrenia: Pathways to Psychosis.

Authors:  Rachel Little; Dale D'Mello
Journal:  Innov Clin Neurosci       Date:  2022 Jul-Sep
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.